




The relative strengths and weaknesses of Respirerx Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Respirerx Pharmaceuticals Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Respirerx Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 275% points.

The company's Economic Capital Ratio, given in the ranking table, is 19%, being 235% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	321
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,601
Liabilities, Non-Current	0
Other Assets	63
Other Compr. Net Income	0
Other Expenses	117
Other Liabilities	0
Other Net Income	1,763
Other Revenues	62
Property and Equipment	17
Research and Development	592
Selling, General and Administrative Expense	3,823

Output Variable	Value in 1000 USD
Assets	400
Liabilities	2,601
Expenses	4,533
Revenues	62
Stockholders Equity	-2,200
Net Income	-2,708
Comprehensive Net Income	-2,708
BaseVar	4,679
ECR before LimitedLiability	-500%
Economic Capital Ratio	19%